Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YH004 in Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma
NCT05564806Phase 1Completed
- Sponsor
- Eucure Biopharma
- Start
- Jan 2023
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of YH004 in solid tumor and non-Hodgkin lymphoma (NHL), sponsored by Eucure Biopharma. Primary endpoints: Adverse Events at 1 year, Maximum Tolerated Dose at 1 year and 1 more. Started Jan 2023; status: completed.
02
Drugs
YH004
03
Conditions
solid tumornon-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT05564806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05564806.